AI Article Synopsis
- Management of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) focuses on careful fluid management and physiological replacement therapy.
- Blood transfusions have specific criteria for use, particularly when dealing with disseminated intravascular coagulation (DIC) during the hemorrhagic phase.
- Preventive transfusions are not beneficial and can lead to longer hospital stays and increased risks of complications like pulmonary edema.
Article Abstract
Management of patients with dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) requires especial care. It is based on physiological replacement therapy and fluid control. The use of blood products has its own criteria, especially during the disseminated intravascular coagulation (DIC) in the hemorrhagic phase. Monitoring bleeding manifestations and laboratory tests are needed. It has been shown that preventive transfusion does not have advantages in the treatment of this disease; on the contrary it increases the length of hospitalization and the development of pulmonary edema, among other transfusion-related risks.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Management of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) focuses on careful fluid management and physiological replacement therapy.
- Blood transfusions have specific criteria for use, particularly when dealing with disseminated intravascular coagulation (DIC) during the hemorrhagic phase.
- Preventive transfusions are not beneficial and can lead to longer hospital stays and increased risks of complications like pulmonary edema.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!